Plain-English translation of NCT07304518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called to see if it can quickly relieve moderate to severe migraines when you use it at the first sign of an attack. Researchers will compare this medication at three different doses against a placebo (a dummy spray with no active ingredient) to find out which dose works best and is safest.
Many people with migraines struggle to find fast, effective relief, especially when other treatments don't work well or cause side effects. This trial aims to develop a new treatment option that could help people manage their migraine attacks more effectively.
You likely qualify if…
You likely don't qualify if…
When you have a moderate to severe migraine, you will use the assigned nasal spray (either the test medication at one of three doses or placebo). You will have about 45 days to experience and treat at least one migraine attack during the study. You'll also complete surveys on a smartphone or tablet to record how well the spray worked and any side effects you experience. The study involves screening appointments to make sure you qualify, and follow-up visits to check your safety and results.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Enrollment target
~456 participants
Started
January 2026
Primary completion
September 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ke Yao
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.